John P. Mueller
John P. Mueller has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- John O'Donnell
Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA
4 shared publications - Ruben Tommasi
Entasis Therapeutics, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
4 shared publications - Alita A. Miller
Entasis Therapeutics, Waltham, Massachusetts, USA
3 shared publications - Alison Luckey
Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland
2 shared publications April Chen
Entasis Therapeutics, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
2 shared publications- Gabrielle Kornmann
Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Vol. 19 (3) , e70515
Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.
Zoliflodacin is a first-in-class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug-resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug-drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin. This was an open label, 2-period, 2-treatment, fixed sequence crossover DDI study. Eighteen eligible adult participants were dosed and completed the study. When zoliflodacin was co-administered with itraconazole at steady state, as determined by itraconazole trough plasma concentrations, zoliflodacin exposure increased as measured by peak concentration (Cmax) by 1.03-fold and by area under the plasma-concentration time curve (AUC) from time 0 to last measurable plasma concentration (AUC0-last) and from time 0 extrapolated to infinity (AUC0-∞) by 1.39- and 1.38-fold, respectively. Eight participants (44.4%) had a total of 15 mild treatment-emergent adverse events (TEAEs), with three considered related to treatment. There were no deaths or serious TEAEs and no participant withdrew. No clinically significant abnormal laboratory values, vital signs, or electrocardiogram findings were reported. In conclusion, the Cmax of zoliflodacin was essentially unchanged (1.03-fold higher) when co-administered with a strong CYP3A4 inhibitor, while AUC exposures increased by less than 1.5-fold, which, combined with an acceptable safety profile, indicate a low DDI potential between zoliflodacin and CYP3A4 inhibitors.
- 1 March 2026
- Vol. 19 (3) , e70515
Open AccessEvaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.
Zoliflodacin is a first-in-class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug-resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug-drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin. This was an open label, 2-period, 2-treatment, fixed sequence crossover DDI study. Eighteen eligible adult participants were dosed and completed the study. When zoliflodacin was co-administered with itraconazole at steady state, as determined by itraconazole trough plasma concentrations, zoliflodacin exposure increased as measured by peak concentration (Cmax) by 1.03-fold and by area under the plasma-concentration time curve (AUC) from time 0 to last measurable plasma concentration (AUC0-last) and from time 0 extrapolated to infinity (AUC0-∞) by 1.39- and 1.38-fold, respectively. Eight participants (44.4%) had a total of 15 mild treatment-emergent adverse events (TEAEs), with three considered related to treatment. There were no deaths or serious TEAEs and no participant withdrew. No clinically significant abnormal laboratory values, vital signs, or electrocardiogram findings were reported. In conclusion, the Cmax of zoliflodacin was essentially unchanged (1.03-fold higher) when co-administered with a strong CYP3A4 inhibitor, while AUC exposures increased by less than 1.5-fold, which, combined with an acceptable safety profile, indicate a low DDI potential between zoliflodacin and CYP3A4 inhibitors.
- Open Access
- 27 February 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (3)
Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants
Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug–drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin. This was an open label, 2‐period, 2‐treatment, fixed sequence crossover DDI study. Eighteen eligible adult participants were dosed and completed the study. When zoliflodacin was co‐administered with itraconazole at steady state, as determined by itraconazole trough plasma concentrations, zoliflodacin exposure increased as measured by peak concentration (C max ) by 1.03‐fold and by area under the plasma‐concentration time curve (AUC) from time 0 to last measurable plasma concentration (AUC 0‐last ) and from time 0 extrapolated to infinity (AUC 0‐∞ ) by 1.39‐ and 1.38‐fold, respectively. Eight participants (44.4%) had a total of 15 mild treatment‐emergent adverse events (TEAEs), with three considered related to treatment. There were no deaths or serious TEAEs and no participant withdrew. No clinically significant abnormal laboratory values, vital signs, or electrocardiogram findings were reported. In conclusion, the C max of zoliflodacin was essentially unchanged (1.03‐fold higher) when co‐administered with a strong CYP3A4 inhibitor, while AUC exposures increased by less than 1.5‐fold, which, combined with an acceptable safety profile, indicate a low DDI potential between zoliflodacin and CYP3A4 inhibitors.
- 27 February 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (3)
Open AccessEvaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants
Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug–drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin. This was an open label, 2‐period, 2‐treatment, fixed sequence crossover DDI study. Eighteen eligible adult participants were dosed and completed the study. When zoliflodacin was co‐administered with itraconazole at steady state, as determined by itraconazole trough plasma concentrations, zoliflodacin exposure increased as measured by peak concentration (C max ) by 1.03‐fold and by area under the plasma‐concentration time curve (AUC) from time 0 to last measurable plasma concentration (AUC 0‐last ) and from time 0 extrapolated to infinity (AUC 0‐∞ ) by 1.39‐ and 1.38‐fold, respectively. Eight participants (44.4%) had a total of 15 mild treatment‐emergent adverse events (TEAEs), with three considered related to treatment. There were no deaths or serious TEAEs and no participant withdrew. No clinically significant abnormal laboratory values, vital signs, or electrocardiogram findings were reported. In conclusion, the C max of zoliflodacin was essentially unchanged (1.03‐fold higher) when co‐administered with a strong CYP3A4 inhibitor, while AUC exposures increased by less than 1.5‐fold, which, combined with an acceptable safety profile, indicate a low DDI potential between zoliflodacin and CYP3A4 inhibitors.
- Open Access
- 1 September 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (9) , 2084-2089
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics
- 1 September 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (9) , 2084-2089
Open AccessChallenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics
- Open Access
- 13 July 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (21) , 12511-12525
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactam antibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over older BLIs in terms of enzymatic spectrum but are limited to the intravenous route of administration. Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor. This new DBO, ETX1317, contains an endocyclic carbon–carbon double bond and a fluoroacetate activating group and exhibits broad spectrum activity against class A, C, and D serine β-lactamases. The ester prodrug of ETX1317, ETX0282, is orally bioavailable and, in combination with cefpodoxime proxetil, is currently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacterales infections.
- 13 July 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (21) , 12511-12525
Open AccessDiscovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactam antibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over older BLIs in terms of enzymatic spectrum but are limited to the intravenous route of administration. Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor. This new DBO, ETX1317, contains an endocyclic carbon–carbon double bond and a fluoroacetate activating group and exhibits broad spectrum activity against class A, C, and D serine β-lactamases. The ester prodrug of ETX1317, ETX0282, is orally bioavailable and, in combination with cefpodoxime proxetil, is currently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacterales infections.
- Open Access
- 7 May 2020
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (6) , 1378-1388
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
Increasingly resistant Enterobacteriaceae have emerged as a health threat in both the hospital and community setting. Infections of the urinary tract, once often treated with oral agents in the community, are requiring increased hospitalization and use of intravenously (IV) administered agents for effective treatment. These isolates often carry Extended Spectrum Beta-Lactamases (ESBLs) and carbapenemases that necessitate the need for an inhibitor to cover a broad range of β-lactamases. ETX1317 is a novel diazabicyclooctane (DBO) class serine β-lactamase inhibitor that restores the antibacterial activity of several classes of β-lactams including 3rd generation cephalosporins such as cefpodoxime (CPD). ETX1317 is currently being developed as an orally available prodrug ETX0282 to be administered with cefpodoxime proxetil (CPDP). The combination has demonstrated oral efficacy in murine models of infection. Pharmacokinetics established in preclinical species and PK/PD attributes suggest the orally administered combination ETX0282+CPDP could serve as an effective treatment option against contemporary ESBL and carbapenemase-producing Enterobacteriaceae.
- 7 May 2020
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (6) , 1378-1388
Open AccessPharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
Increasingly resistant Enterobacteriaceae have emerged as a health threat in both the hospital and community setting. Infections of the urinary tract, once often treated with oral agents in the community, are requiring increased hospitalization and use of intravenously (IV) administered agents for effective treatment. These isolates often carry Extended Spectrum Beta-Lactamases (ESBLs) and carbapenemases that necessitate the need for an inhibitor to cover a broad range of β-lactamases. ETX1317 is a novel diazabicyclooctane (DBO) class serine β-lactamase inhibitor that restores the antibacterial activity of several classes of β-lactams including 3rd generation cephalosporins such as cefpodoxime (CPD). ETX1317 is currently being developed as an orally available prodrug ETX0282 to be administered with cefpodoxime proxetil (CPDP). The combination has demonstrated oral efficacy in murine models of infection. Pharmacokinetics established in preclinical species and PK/PD attributes suggest the orally administered combination ETX0282+CPDP could serve as an effective treatment option against contemporary ESBL and carbapenemase-producing Enterobacteriaceae.
- Open Access
Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)
Previously, we reported potent activity of a novel spiropyrimidinetrione, zoliflodacin, against N. gonorrhoeae isolates from symptomatic men in Nanjing, China, collected in 2013. Here, we investigated trends of susceptibilities of zoliflodacin in 986 gonococcal isolates collected from men between 2014 and 2018. N. gonorrhoeae isolates were tested for susceptibility to zoliflodacin and seven other antibiotics. Mutations in gyrA, gyrB, parC and parE genes were determined by PCR and DNA sequencing. The MIC of zoliflodacin for N. gonorrhoeae ranged from ≤0.002 to 0.25 mg/L; the overall MIC 50 s and MIC 90 s were 0.06 mg/L and 0.125mg/L in 2018, increasing two-fold from 2014. However, the percent of isolates with lower zoliflodacin MICs declined in each year sequentially while the percent with higher MICs increased yearly (P≤0.00001). All isolates were susceptible to spectinomycin but resistant to ciprofloxacin (MIC ≥1 μg/ml); 21.2% (209/986) were resistant to azithromycin (≥1 μg/ml), 43.4% (428/986) were penicillinase-producing (PPNG), 26.9% (265/986) tetracycline-resistant (TRNG) and 19.4% (191/986) were multi-drug resistant (MDR) isolates. Among 143 isolates with higher zoliflodacin MICs (0.125-0.25 mg/L), all had quinolone resistance associated double or triple mutations in gyrA ; 139/143 (97.2%) also had mutations in parC . There were no D429N/A and/or K450T mutations in GyrB identified in the 143 isolates with higher zoliflodacin MICs; a S467N mutation in GyrB was identified in one isolate. We report that zoliflodacin has excellent in vitro activity against clinical gonococcal isolates, including those with high-level resistance to ciprofloxacin, azithromycin and extended spectrum cephalosporins.
Open AccessSusceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)
Previously, we reported potent activity of a novel spiropyrimidinetrione, zoliflodacin, against N. gonorrhoeae isolates from symptomatic men in Nanjing, China, collected in 2013. Here, we investigated trends of susceptibilities of zoliflodacin in 986 gonococcal isolates collected from men between 2014 and 2018. N. gonorrhoeae isolates were tested for susceptibility to zoliflodacin and seven other antibiotics. Mutations in gyrA, gyrB, parC and parE genes were determined by PCR and DNA sequencing. The MIC of zoliflodacin for N. gonorrhoeae ranged from ≤0.002 to 0.25 mg/L; the overall MIC 50 s and MIC 90 s were 0.06 mg/L and 0.125mg/L in 2018, increasing two-fold from 2014. However, the percent of isolates with lower zoliflodacin MICs declined in each year sequentially while the percent with higher MICs increased yearly (P≤0.00001). All isolates were susceptible to spectinomycin but resistant to ciprofloxacin (MIC ≥1 μg/ml); 21.2% (209/986) were resistant to azithromycin (≥1 μg/ml), 43.4% (428/986) were penicillinase-producing (PPNG), 26.9% (265/986) tetracycline-resistant (TRNG) and 19.4% (191/986) were multi-drug resistant (MDR) isolates. Among 143 isolates with higher zoliflodacin MICs (0.125-0.25 mg/L), all had quinolone resistance associated double or triple mutations in gyrA ; 139/143 (97.2%) also had mutations in parC . There were no D429N/A and/or K450T mutations in GyrB identified in the 143 isolates with higher zoliflodacin MICs; a S467N mutation in GyrB was identified in one isolate. We report that zoliflodacin has excellent in vitro activity against clinical gonococcal isolates, including those with high-level resistance to ciprofloxacin, azithromycin and extended spectrum cephalosporins.
- 24 April 2020
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (6) , 1332-1345
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates
The CDC and World Health Organization have issued a list of priority pathogens for which there are dwindling therapeutic options, including antibiotic-resistant N. gonorrhoeae, for which novel, oral agents are urgently needed. Zoliflodacin, the first in a new class of antibacterial agents called the spiropyrimidinetriones, is being developed for the treatment of gonorrhea. It has a unique mode-of-inhibition against bacterial type II topoisomerases with binding sites in bacterial gyrase that are distinct from those of the fluoroquinolones. Zoliflodacin is bactericidal, with a low frequency of resistance and potent antibacterial activity against N. gonorrhoeae, including multi-drug resistant strains (MICs ranging from ≤0.002 - 0.25 µg/mL). Although being developed for the treatment of gonorrhea, zoliflodacin also has activity against Gram-positive, fastidious Gram-negative and atypical pathogens. A hollow-fiber infection model using S. aureus showed that that pharmacokinetic/pharmacodynamic (PK/PD) index of fAUC/MIC best correlated with efficacy in in vivo neutropenic thigh models in mice. This data and unbound exposure magnitudes derived from the thigh models were subsequently utilized in a surrogate pathogen approach to establish dose ranges for clinical development with N. gonorrhoeae. In preclinical studies, a wide safety margin supported progression to Phase 1 studies in healthy volunteers, which showed linear pharmacokinetics, good oral bioavailability and no significant safety findings. In a Phase 2 study, zoliflodacin was effective in treating gonococcal urogenital and rectal infections. In partnership with GARDP, zoliflodacin is currently being studied in a global Phase 3 clinical trial. Zoliflodacin represents a promising new therapy for drug resistant infections caused by N. gonorrhoeae.
- 24 April 2020
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (6) , 1332-1345
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates
The CDC and World Health Organization have issued a list of priority pathogens for which there are dwindling therapeutic options, including antibiotic-resistant N. gonorrhoeae, for which novel, oral agents are urgently needed. Zoliflodacin, the first in a new class of antibacterial agents called the spiropyrimidinetriones, is being developed for the treatment of gonorrhea. It has a unique mode-of-inhibition against bacterial type II topoisomerases with binding sites in bacterial gyrase that are distinct from those of the fluoroquinolones. Zoliflodacin is bactericidal, with a low frequency of resistance and potent antibacterial activity against N. gonorrhoeae, including multi-drug resistant strains (MICs ranging from ≤0.002 - 0.25 µg/mL). Although being developed for the treatment of gonorrhea, zoliflodacin also has activity against Gram-positive, fastidious Gram-negative and atypical pathogens. A hollow-fiber infection model using S. aureus showed that that pharmacokinetic/pharmacodynamic (PK/PD) index of fAUC/MIC best correlated with efficacy in in vivo neutropenic thigh models in mice. This data and unbound exposure magnitudes derived from the thigh models were subsequently utilized in a surrogate pathogen approach to establish dose ranges for clinical development with N. gonorrhoeae. In preclinical studies, a wide safety margin supported progression to Phase 1 studies in healthy volunteers, which showed linear pharmacokinetics, good oral bioavailability and no significant safety findings. In a Phase 2 study, zoliflodacin was effective in treating gonococcal urogenital and rectal infections. In partnership with GARDP, zoliflodacin is currently being studied in a global Phase 3 clinical trial. Zoliflodacin represents a promising new therapy for drug resistant infections caused by N. gonorrhoeae.
- 1 January 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (1)
Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers
Zoliflodacin is a novel spiropyrimidinetrione with activity against bacterial Type II topoisomerases that inhibits DNA biosynthesis and results in accumulation of double strand cleavages in bacteria. We report results from two Phase 1 studies that investigated the safety, tolerability, and pharmacokinetics (PK) of zoliflodacin, and the absorption, distribution, metabolism, and excretion (ADME) after single doses in healthy volunteers. In the single ascending dose study, zoliflodacin was rapidly absorbed with a Tmax between 1.5 and 2.3 h. Exposure increased dose proportionally up to 800 mg, and less than dose proportionally between 800 and 4000 mg. Urinary excretion of unchanged zoliflodacin was >5.0% of the total dose. In the fed state, absorption was delayed (Tmax 4 h), accompanied by an increase in the AUC at 1500 and 3000 mg doses. In the ADME study (3000 mg PO), the PK profile of zoliflodacin had similar exposure (AUC and Cmax) to the ascending dose study and a median Tmax of 2.5 hours. A total of 97.8% of the administered radioactivity was recovered in excreta, with urine and fecal elimination accounting for approximately 18.2% and 79.6% of the dose, respectively. The major clearance pathway was via metabolism and elimination in feces with low urinary recovery of unchanged drug (approximately 2.5%) and metabolites accounting for 56% of the dose excreted in the feces. Zoliflodacin represented 72.3% and metabolite M3 accounted for 16.4% of total circulating radioactivity in human plasma. Along with the results from these studies and based upon the safety, PK, and the PK/PD targets, a dosage regimen was selected for evaluation in a Phase 2 study in urogenital gonorrhea.
- 1 January 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (1)
Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers
Zoliflodacin is a novel spiropyrimidinetrione with activity against bacterial Type II topoisomerases that inhibits DNA biosynthesis and results in accumulation of double strand cleavages in bacteria. We report results from two Phase 1 studies that investigated the safety, tolerability, and pharmacokinetics (PK) of zoliflodacin, and the absorption, distribution, metabolism, and excretion (ADME) after single doses in healthy volunteers. In the single ascending dose study, zoliflodacin was rapidly absorbed with a Tmax between 1.5 and 2.3 h. Exposure increased dose proportionally up to 800 mg, and less than dose proportionally between 800 and 4000 mg. Urinary excretion of unchanged zoliflodacin was >5.0% of the total dose. In the fed state, absorption was delayed (Tmax 4 h), accompanied by an increase in the AUC at 1500 and 3000 mg doses. In the ADME study (3000 mg PO), the PK profile of zoliflodacin had similar exposure (AUC and Cmax) to the ascending dose study and a median Tmax of 2.5 hours. A total of 97.8% of the administered radioactivity was recovered in excreta, with urine and fecal elimination accounting for approximately 18.2% and 79.6% of the dose, respectively. The major clearance pathway was via metabolism and elimination in feces with low urinary recovery of unchanged drug (approximately 2.5%) and metabolites accounting for 56% of the dose excreted in the feces. Zoliflodacin represented 72.3% and metabolite M3 accounted for 16.4% of total circulating radioactivity in human plasma. Along with the results from these studies and based upon the safety, PK, and the PK/PD targets, a dosage regimen was selected for evaluation in a Phase 2 study in urogenital gonorrhea.
- Open Access
- 25 October 2016
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 3 (suppl_1)
Global Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014
Background. Multidrug-resistant Acinetobacter baumannii infections are considered a serious threat by the Centers for Disease Control and other government agencies. They are among the most difficult to treat and are associated with high mortality rates due to the limited number of effective therapies available and inappropriate initial treatment choice. The novel diazabicyclooctenone β-lactamase inhibitor effectively restores the antibacterial activity of sulbactam against multidrug-resistant (MDR) A. baumannii due to its potent inhibition of class A, C, and D serine β-lactamases, which are commonly found in this organism.
- 25 October 2016
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 3 (suppl_1)
Open AccessGlobal Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014
Background. Multidrug-resistant Acinetobacter baumannii infections are considered a serious threat by the Centers for Disease Control and other government agencies. They are among the most difficult to treat and are associated with high mortality rates due to the limited number of effective therapies available and inappropriate initial treatment choice. The novel diazabicyclooctenone β-lactamase inhibitor effectively restores the antibacterial activity of sulbactam against multidrug-resistant (MDR) A. baumannii due to its potent inhibition of class A, C, and D serine β-lactamases, which are commonly found in this organism.